메뉴 건너뛰기




Volumn 9, Issue 1, 2013, Pages 671-680

Association between triglycerides and cardiovascular events in primary populations: A meta-regression analysis and synthesis of evidence

Author keywords

Cardiovascular diseases; Cholesterol; Risk factors; Triglycerides

Indexed keywords

EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

EID: 84889800717     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S52713     Document Type: Article
Times cited : (29)

References (69)
  • 1
    • 26244432388 scopus 로고    scopus 로고
    • Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
    • (2005) Lancet , vol.366 , Issue.9493 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 2
    • 3142729178 scopus 로고    scopus 로고
    • National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
    • (2004) Circulation , vol.110 , Issue.2 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 3
    • 67449094503 scopus 로고    scopus 로고
    • Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
    • Robinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vasc Health Risk Manag. 2009;5(1):31-43.
    • (2009) Vasc Health Risk Manag , vol.5 , Issue.1 , pp. 31-43
    • Robinson, J.G.1
  • 4
    • 33644810298 scopus 로고    scopus 로고
    • Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
    • British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society
    • British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91 Suppl 5:v1-v52.
    • (2005) Heart , vol.91 , Issue.SUPPL. 5
  • 5
    • 35148892823 scopus 로고    scopus 로고
    • European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: Executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
    • Graham I, Atar D, Borch-Johnsen K, et al; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28(19):2375-2414.
    • (2007) Eur Heart J , vol.28 , Issue.19 , pp. 2375-2414
    • Graham, I.1    Atar, D.2    Borch-Johnsen, K.3
  • 6
    • 79958148945 scopus 로고    scopus 로고
    • European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management
    • Chapman MJ, Ginsberg HN, Amarenco P, et al; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-1361.
    • (2011) Eur Heart J , vol.32 , Issue.11 , pp. 1345-1361
    • Chapman, M.J.1    Ginsberg, H.N.2    Amarenco, P.3
  • 7
    • 11844296800 scopus 로고    scopus 로고
    • Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
    • Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2): 185-197.
    • (2005) J Am Coll Cardiol , vol.45 , Issue.2 , pp. 185-197
    • Birjmohun, R.S.1    Hutten, B.A.2    Kastelein, J.J.3    Stroes, E.S.4
  • 8
    • 77952397461 scopus 로고    scopus 로고
    • Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    • Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353-361.
    • (2010) Atherosclerosis , vol.210 , Issue.2 , pp. 353-361
    • Bruckert, E.1    Labreuche, J.2    Amarenco, P.3
  • 9
    • 0021350001 scopus 로고
    • Reduction in incidence of coronary heart disease
    • The Lipid Research Clinics Coronary Primary Prevention Trial results. I
    • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3): 351-364.
    • (1984) JAMA , vol.251 , Issue.3 , pp. 351-364
  • 10
    • 0026582213 scopus 로고
    • Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
    • Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339(8793): 563-569.
    • (1992) Lancet , vol.339 , Issue.8793 , pp. 563-569
    • Watts, G.F.1    Lewis, B.2    Brunt, J.N.3
  • 11
    • 79951552544 scopus 로고    scopus 로고
    • Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta-analysis
    • Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57(2):267-272.
    • (2011) J Cardiovasc Pharmacol , vol.57 , Issue.2 , pp. 267-272
    • Bruckert, E.1    Labreuche, J.2    Deplanque, D.3    Touboul, P.J.4    Amarenco, P.5
  • 12
    • 79953867783 scopus 로고    scopus 로고
    • Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis
    • Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92.
    • (2009) BMJ , vol.338
    • Briel, M.1    Ferreira-Gonzalez, I.2    You, J.J.3
  • 13
    • 77956230837 scopus 로고    scopus 로고
    • Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: Systematic review and meta-regression analysis
    • Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis. 2010;212(1):9-15.
    • (2010) Atherosclerosis , vol.212 , Issue.1 , pp. 9-15
    • Labreuche, J.1    Deplanque, D.2    Touboul, P.J.3    Bruckert, E.4    Amarenco, P.5
  • 14
    • 33750897238 scopus 로고    scopus 로고
    • Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-analysis of 23 randomized lipid trials
    • Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006;17(6):631-636.
    • (2006) Curr Opin Lipidol , vol.17 , Issue.6 , pp. 631-636
    • Brown, B.G.1    Stukovsky, K.H.2    Zhao, X.Q.3
  • 16
    • 3042570661 scopus 로고    scopus 로고
    • Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials
    • Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract. 2003;4:18.
    • (2003) BMC Fam Pract , vol.4 , pp. 18
    • Edwards, J.E.1    Moore, R.A.2
  • 17
    • 34547748349 scopus 로고    scopus 로고
    • Cholesterol reduction yields clinical benefits: Meta-analysis including recent trials
    • Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 2007;29(5):778-794.
    • (2007) Clin Ther , vol.29 , Issue.5 , pp. 778-794
    • Gould, A.L.1    Davies, G.M.2    Alemao, E.3    Yin, D.D.4    Cook, J.R.5
  • 18
    • 0037132607 scopus 로고    scopus 로고
    • The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
    • (2002) JAMA , vol.288 , Issue.23 , pp. 2998-3007
  • 19
    • 33746895436 scopus 로고    scopus 로고
    • Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack
    • Amarenco P, Bogousslavsky J, Callahan A, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
    • (2006) N Engl J Med , vol.355 , Issue.6 , pp. 549-559
    • Amarenco, P.1    Bogousslavsky, J.2    Callahan, A.3
  • 20
    • 41649107358 scopus 로고    scopus 로고
    • ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia
    • Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431-1443.
    • (2008) N Engl J Med , vol.358 , Issue.14 , pp. 1431-1443
    • Kastelein, J.J.1    Akdim, F.2    Stroes, E.S.3
  • 21
    • 4344683381 scopus 로고    scopus 로고
    • CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
    • Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
    • (2004) Lancet , vol.364 , Issue.9435 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 22
    • 28044452217 scopus 로고    scopus 로고
    • FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.
    • (2005) Lancet , vol.366 , Issue.9500 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 23
    • 84864219466 scopus 로고    scopus 로고
    • ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
    • Bosch J, Gerstein HC, Dagenais GR, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.
    • (2012) N Engl J Med , vol.367 , Issue.4 , pp. 309-318
    • Bosch, J.1    Gerstein, H.C.2    Dagenais, G.R.3
  • 24
    • 77951704587 scopus 로고    scopus 로고
    • ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus
    • Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
    • (2010) N Engl J Med , vol.362 , Issue.17 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 25
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
    • (2002) Lancet , vol.360 , Issue.9326 , pp. 7-22
  • 26
    • 0036357179 scopus 로고    scopus 로고
    • Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT)
    • Koizumi J, Shimizu M, Miyamoto S, Origasa H, Mabuchi H. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). J Atheroscler Thromb. 2002;9(5):251-259.
    • (2002) J Atheroscler Thromb , vol.9 , Issue.5 , pp. 251-259
    • Koizumi, J.1    Shimizu, M.2    Miyamoto, S.3    Origasa, H.4    Mabuchi, H.5
  • 27
    • 0037164314 scopus 로고    scopus 로고
    • PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
    • Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
    • (2002) Lancet , vol.360 , Issue.9346 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3
  • 28
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
    • (1998) JAMA , vol.279 , Issue.20 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 29
    • 0037420492 scopus 로고    scopus 로고
    • ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlöf, B.2    Poulter, N.R.3
  • 30
    • 0023726344 scopus 로고
    • Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
    • Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260(5):641-651.
    • (1988) JAMA , vol.260 , Issue.5 , pp. 641-651
    • Manninen, V.1    Elo, M.O.2    Frick, M.H.3
  • 31
    • 56749106312 scopus 로고    scopus 로고
    • JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
    • (2008) N Engl J Med , vol.359 , Issue.21 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 32
    • 33947713026 scopus 로고    scopus 로고
    • METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial
    • Crouse JR, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
    • (2007) JAMA , vol.297 , Issue.12 , pp. 1344-1353
    • Crouse, J.R.1    Raichlen, J.S.2    Riley, W.A.3
  • 33
    • 33748952489 scopus 로고    scopus 로고
    • MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial
    • Nakamura H, Arakawa K, Itakura H, et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163.
    • (2006) Lancet , vol.368 , Issue.9542 , pp. 1155-1163
    • Nakamura, H.1    Arakawa, K.2    Itakura, H.3
  • 34
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
    • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
    • (1995) N Engl J Med , vol.333 , Issue.20 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 35
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
    • (1994) Lancet , vol.344 , Issue.8934 , pp. 1383-1389
  • 36
    • 19944426989 scopus 로고    scopus 로고
    • A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events
    • Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142(2):95-104.
    • (2005) Ann Intern Med , vol.142 , Issue.2 , pp. 95-104
    • Whitney, E.J.1    Krasuski, R.A.2    Personius, B.E.3
  • 37
    • 84855171302 scopus 로고    scopus 로고
    • AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • Boden WE, Probstfield JL, Anderson T, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
    • (2011) N Engl J Med , vol.365 , Issue.24 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2    Anderson, T.3
  • 38
    • 7044222840 scopus 로고    scopus 로고
    • Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study
    • ALLIANCE Investigators
    • Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772-1779.
    • (2004) J Am Coll Cardiol , vol.44 , Issue.9 , pp. 1772-1779
    • Koren, M.J.1    Hunninghake, D.B.2
  • 39
    • 4544243333 scopus 로고    scopus 로고
    • Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
    • de Lemos JA, Blazing MA, Wiviott SD, et al; Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307-1316.
    • (2004) JAMA , vol.292 , Issue.11 , pp. 1307-1316
    • de Lemos, J.A.1    Blazing, M.A.2    Wiviott, S.D.3
  • 40
    • 0029982038 scopus 로고    scopus 로고
    • Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
    • Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347(9005):849-853.
    • (1996) Lancet , vol.347 , Issue.9005 , pp. 849-853
    • Ericsson, C.G.1    Hamsten, A.2    Nilsson, J.3    Grip, L.4    Svane, B.5    de Faire, U.6
  • 41
    • 38349138583 scopus 로고    scopus 로고
    • Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: An extended follow-up of the BIP trial
    • BIP Study Group
    • Goldenberg I, Benderly M, Goldbourt U; BIP Study Group. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol. 2008;51(4): 459-465.
    • (2008) J Am Coll Cardiol , vol.51 , Issue.4 , pp. 459-465
    • Goldenberg, I.1    Benderly, M.2    Goldbourt, U.3
  • 42
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
    • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
    • (1996) N Engl J Med , vol.335 , Issue.14 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 43
    • 0034526070 scopus 로고    scopus 로고
    • Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: Do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)
    • Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J. 2000;1(12):810-820.
    • (2000) Ital Heart J , vol.1 , Issue.12 , pp. 810-820
  • 44
    • 2542497645 scopus 로고    scopus 로고
    • GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
    • Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004;20(5):627-637.
    • (2004) Curr Med Res Opin , vol.20 , Issue.5 , pp. 627-637
    • Athyros, V.G.1    Mikhailidis, D.P.2    Papageorgiou, A.A.3
  • 45
    • 0035969564 scopus 로고    scopus 로고
    • Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    • Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.
    • (2001) N Engl J Med , vol.345 , Issue.22 , pp. 1583-1592
    • Brown, B.G.1    Zhao, X.Q.2    Chait, A.3
  • 46
    • 0032547326 scopus 로고    scopus 로고
    • Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
    • Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613.
    • (1998) JAMA , vol.280 , Issue.7 , pp. 605-613
    • Hulley, S.1    Grady, D.2    Bush, T.3
  • 47
    • 0027419415 scopus 로고
    • Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population
    • Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Mänttäri M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993;25(1):41-45.
    • (1993) Ann Med , vol.25 , Issue.1 , pp. 41-45
    • Frick, M.H.1    Heinonen, O.P.2    Huttunen, J.K.3    Koskinen, P.4    Mänttäri, M.5    Manninen, V.6
  • 48
    • 27744603499 scopus 로고    scopus 로고
    • Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
    • Pedersen TR, Faergeman O, Kastelein JJ, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-2445.
    • (2005) JAMA , vol.294 , Issue.19 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3
  • 49
    • 0032487931 scopus 로고    scopus 로고
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-1357.
    • (1998) N Engl J Med , vol.339 , Issue.19 , pp. 1349-1357
  • 50
    • 0035804846 scopus 로고    scopus 로고
    • Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
    • Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
    • (2001) JAMA , vol.285 , Issue.13 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 51
    • 0031030620 scopus 로고    scopus 로고
    • The Post Coronary Artery Bypass Graft Trial Investigators
    • The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
    • The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med. 1997;336(3): 153-162.
    • (1997) N Engl J Med , vol.336 , Issue.3 , pp. 153-162
  • 52
    • 0028849703 scopus 로고
    • Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I):Reduction in atherosclerosis progression and clinical events. PLAC I investigation
    • Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I):reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 1995;26(5):1133-1139.
    • (1995) J Am Coll Cardiol , vol.26 , Issue.5 , pp. 1133-1139
    • Pitt, B.1    Mancini, G.B.2    Ellis, S.G.3    Rosman, H.S.4    Park, J.S.5    McGovern, M.E.6
  • 53
    • 0029050796 scopus 로고
    • Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
    • Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91(10):2528-2540.
    • (1995) Circulation , vol.91 , Issue.10 , pp. 2528-2540
    • Jukema, J.W.1    Bruschke, A.V.2    van Boven, A.J.3
  • 54
    • 15944410609 scopus 로고    scopus 로고
    • Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
    • (2005) N Engl J Med , vol.352 , Issue.14 , pp. 1425-1435
    • Larosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 55
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    • Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-418.
    • (1999) N Engl J Med , vol.341 , Issue.6 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 56
    • 67449100023 scopus 로고    scopus 로고
    • The independent relationship between triglycerides and coronary heart disease
    • Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag. 2009;5(1):89-95.
    • (2009) Vasc Health Risk Manag , vol.5 , Issue.1 , pp. 89-95
    • Morrison, A.1    Hokanson, J.E.2
  • 57
    • 85027956925 scopus 로고    scopus 로고
    • American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association
    • Miller M, Stone NJ, Ballantyne C, et al; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292-2333.
    • (2011) Circulation , vol.123 , Issue.20 , pp. 2292-2333
    • Miller, M.1    Stone, N.J.2    Ballantyne, C.3
  • 58
    • 0037490080 scopus 로고    scopus 로고
    • Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis
    • Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
    • (2003) BMJ , vol.326 , Issue.7404 , pp. 1423
    • Law, M.R.1    Wald, N.J.2    Rudnicka, A.R.3
  • 59
    • 33750477286 scopus 로고    scopus 로고
    • Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
    • Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48(9):1774-1781.
    • (2006) J Am Coll Cardiol , vol.48 , Issue.9 , pp. 1774-1781
    • Davidson, M.H.1    McKenney, J.M.2    Shear, C.L.3    Revkin, J.H.4
  • 60
    • 0043011486 scopus 로고    scopus 로고
    • Gemcabene Study Group. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    • Bays HE, McKenney JM, Dujovne CA, et al; Gemcabene Study Group. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003;92(5):538-543.
    • (2003) Am J Cardiol , vol.92 , Issue.5 , pp. 538-543
    • Bays, H.E.1    McKenney, J.M.2    Dujovne, C.A.3
  • 61
    • 0033536024 scopus 로고    scopus 로고
    • Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis
    • Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99(22):2901-2907.
    • (1999) Circulation , vol.99 , Issue.22 , pp. 2901-2907
    • Wittrup, H.H.1    Tybjaerg-Hansen, A.2    Nordestgaard, B.G.3
  • 62
    • 0033396880 scopus 로고    scopus 로고
    • Functional variants in the lipoprotein lipase gene and risk cardiovascular disease
    • Hokanson JE. Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Curr Opin Lipidol. 1999;10(5):393-399.
    • (1999) Curr Opin Lipidol , vol.10 , Issue.5 , pp. 393-399
    • Hokanson, J.E.1
  • 63
    • 0032792469 scopus 로고    scopus 로고
    • A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: The Framingham Offspring Study
    • Gagné SE, Larson MG, Pimstone SN, et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin Genet. 1999;55(6):450-454.
    • (1999) Clin Genet , vol.55 , Issue.6 , pp. 450-454
    • Gagné, S.E.1    Larson, M.G.2    Pimstone, S.N.3
  • 64
    • 33748745775 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases
    • Hu Y, Liu W, Huang R, Zhang X. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases. J Lipid Res. 2006;47(9):1908-1914.
    • (2006) J Lipid Res , vol.47 , Issue.9 , pp. 1908-1914
    • Hu, Y.1    Liu, W.2    Huang, R.3    Zhang, X.4
  • 65
    • 45349105911 scopus 로고    scopus 로고
    • Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
    • Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777-2788.
    • (2008) JAMA , vol.299 , Issue.23 , pp. 2777-2788
    • Thompson, A.1    Di Angelantonio, E.2    Sarwar, N.3
  • 66
    • 77951875017 scopus 로고    scopus 로고
    • Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies
    • Sarwar N, Sandhu MS, Ricketts SL, et al; Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634-1639.
    • (2010) Lancet , vol.375 , Issue.9726 , pp. 1634-1639
    • Sarwar, N.1    Sandhu, M.S.2    Ricketts, S.L.3
  • 67
    • 44649140474 scopus 로고    scopus 로고
    • Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease
    • Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524-2532.
    • (2008) JAMA , vol.299 , Issue.21 , pp. 2524-2532
    • Frikke-Schmidt, R.1    Nordestgaard, B.G.2    Stene, M.C.3
  • 68
    • 70450081001 scopus 로고    scopus 로고
    • Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease
    • Di Angelantonio E, Sarwar N, Perry P, et al; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
    • (2009) JAMA , vol.302 , Issue.18 , pp. 1993-2000
    • Di Angelantonio, E.1    Sarwar, N.2    Perry, P.3
  • 69
    • 33846637379 scopus 로고    scopus 로고
    • Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies
    • Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 2007;115(4): 450-458.
    • (2007) Circulation , vol.115 , Issue.4 , pp. 450-458
    • Sarwar, N.1    Danesh, J.2    Eiriksdottir, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.